Newsgroup: it.economia.borsa.estero
Titolo: Bart, le VRA...

....la news che aspettavi.
Mi sembra questo sia il trampolino di lancio.
Una sorta di resa dei conti.
Ma il fatto di esserci su questo trampolino à gia qualcosa.....
Non è da tutti poterci salire. O sbaglio?
22/7

 Non è da tutti poterci salire. O sbaglio?
beh, basta comprarle finche' no sono partite, e per adesso ancora sono a
0,33 :-))
=========================================
Viragen Featured In Biomanufacturing Report
Thursday September 18, 8:29 am ET
PLANTATION, Fla., Sept. 18 /PRNewswire-FirstCall/ -- Viragen, Inc. (Amex:
VRA - News) today announced that the Company's Avian Transgenic
Biomanufacturing Technology is included in a research report which provides
a comprehensive market analysis of the biopharmaceutical contract
manufacturing market worldwide.
HighTech Business Decisions conducted the market research and wrote the
report "Biopharmaceutical Contract Manufacturing: Serving the Growing Need
for Biopharmaceutical Production". Viragen's Avian Transgenic Technology is
featured in a portion of the report which profiles plans for using
transgenic technologies as a potential solution for producing
biopharmaceuticals that require very large volumes.
The August 2003 report is considered the most comprehensive and current
industry report on biopharmaceutical contract manufacturing. For more
information, please visit 
http://www.hightechdecisions.com
About Avian Transgenic Technology
Viragen holds the worldwide exclusive license to commercialize Avian
Transgenic Technology as granted by Roslin Institute. This project is
designed to substitute chicken eggs for expensive bioreactor vessels
presently used in the manufacture of protein-based drugs. Upon the
successful completion of this project, flocks of specially produced
transgenic chickens would lay virtually unlimited numbers of eggs which
would have significant amounts of the target drug in the egg whites. The
proportion of protein drugs, including monoclonal antibodies, under
development is forecast to be expanding rapidly and manufacturing
constraints, including lack of adequate facilities, have been recognized.
About Viragen, Inc.
Viragen is a biotechnology company specializing in the research, development
and commercialization of natural and recombinant protein-based drugs
designed to treat a broad range of viral and malignant diseases. These
protein-based drugs include natural human alpha interferon, monoclonal
antibodies, peptide drugs and therapeutic vaccines. Viragen's strategy also
includes the development of Avian Transgenic Technology for the large-scale,
cost-effective manufacturing of its portfolio of protein-based drugs, as
well as offering Contract Manufacturing for the biopharmaceutical industry.
Viragen is publicly traded on the American Stock Exchange (VRA). Viragen's
majority owned subsidiary, Viragen International, Inc., is publicly traded
on the Over-The-Counter Bulletin Board (VGNI). Viragen's key partners and
licensors include: Roslin Institute, Memorial Sloan-Kettering Cancer Center,
National Institutes of Health, Cancer Research UK, University of Nottingham
(U.K.), University of Miami, America's Blood Centers and the German Red
Cross.
Viragen, Inc. Corporate Contact:
Douglas Calder, Director of CommunicationsPhone: 
(954) 233-8746
;
Fax: 
(954) 233-1414
 E-mail: 
dca...@viragen.com
The foregoing press announcement contains forward-looking statements that
can be identified by such terminology such as "expect", "potential",
"suggests", "may", "will", "should", "could" or similar expressions. Such
forward-looking statements involve known and unknown risks, uncertainties
and other factors that may cause the actual results to be materially
different from any future results, performance or achievements expressed or
implied by such statements. In particular, management's expectations
regarding future research, development and/or commercial results could be
affected by, among other things, uncertainties relating to clinical trials
and product development; availability of future financing; unexpected
regulatory delays or government regulation generally; the Company's ability
to obtain or maintain patent and other proprietary intellectual property
protection; and competition in general. Forward-looking statements speak
only as to the date they are made. The Company does not undertake to update
forward-looking statements to reflect circumstances or events that occur
after the date the forward-looking statements are made.

 bankrupty :-((
Uno chi?
Greenspan?
^_^
22/7

 Dovrebbe uscire anche su Yahoo tra massimo 45 minuti....
e tu dove l'hai letta?? nel board non trovo nulla, puoi fare un
copia/incolla?
il book e' quasi fermo, solo un po' piu' di gorgoglio rispetto ai giorni
scorsi, non dovrebbe esserci piu' movimento ad una notizia del genere?
thank

 thank
Ci ho messo la faccina bart, ci ho messo la faccina....!!
Grrrrrrr
22/7

> Ci ho messo la faccina bart, ci ho messo la faccina....!!
eeehhh, co 'ste faccine!! :-))
nonostate la new cmq e' quasi ferma... boh
guardo con NVIDIA :-) la salita di adsx...